SEC Form 4 · accession 0001803424-26-000004
Vaxcyte, Inc. · PCVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Markels
Director
Period of report
Jul 16, 2026
Accepted (ET)
Jul 16, 2026 · 4:56 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001649094
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $56.04 | Jul 16, 2026 | A | 23,029 | A | — | Jul 16, 2036 | Common Stock | 23,029 | 23,029 | D |
Explanation of responses
- F1Option shall vest over 36 months, 1/3 of which will vest on July 16, 2027 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.